China SXT Pharmaceuticals, Inc. (SXTC) stock
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
$3.00+0.27 (+9.89%)
Close on Nov 13, 2026Market cap $2.87MP/E –Yield –
China SXT Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2026 it was 21.9%, against 21.1% the year before. The highest annual figure on record is 65.8% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | 21.9% | +0.7 |
| FY2025 | Mar 31, 2025 | 21.1% | −7.6 |
| FY2024 | Mar 31, 2024 | 28.7% | +7.1 |
| FY2023 | Mar 31, 2023 | 21.6% | −26.5 |
| FY2022 | Mar 31, 2022 | 48.1% | −11.3 |
| FY2021 | Mar 31, 2021 | 59.4% | +7.1 |
| FY2020 | Mar 31, 2020 | 52.4% | −13.4 |
| FY2019 | Mar 31, 2019 | 65.8% | +17.3 |
| FY2018 | Mar 31, 2018 | 48.5% | +1.1 |
| FY2017 | Mar 31, 2017 | 47.4% | – |
See a number that looks wrong?